<DOC>
	<DOCNO>NCT01063712</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness device `` Nit-Occlud速 PDA-R '' percutaneous closure patent ductus .</brief_summary>
	<brief_title>Safety Effectiveness Device `` Nit-Occlud速 PDA-R ''</brief_title>
	<detailed_description>During year 2003 2008 , Cardiological Medical Center `` Kardiozentrum '' evaluate 1136 patient echocardiographic study , 14.7 % patient diagnosed patent arterial duct . The PDA abnormal communication aorta pulmonary artery . Untreated rise intrapulmonary pressure lead serious complication like cardiac insufficiency . The incidence duct isolated heart disease 3.6 7 % congenital heart diseases sea level , 10 - 14 % high altitude ; rise 20 % city 2.500 sea level . The duct high altitude generally wide large sea level . One treatment alternative percutaneous transluminal implantation permanent implant close defect . The device investigation `` Nit-Occlud速 PDA-R '' develop closure PDA minimal diameter 2-8 mm . The device performs function generate defect occlusion body . The implant stimulate body generate epithelium implant PDA close .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<criteria>Clinical echocardiographic compatibility PDA without associate heart disease require surgical solution Minimum diameter PDA 2 8 mm Systolic pulmonary pressure measure cardiac catheterization , pas 2/3 value systolic systemic pressure Weight high 10 kg , regardless age Patients diagnose recruited period 2009 2010 Patients trisomy 21 also fulfill previous criterion , number patient T21 exceed 10 % entire group patient . letter consent sign parent legal guardian Relative Infections occur acute bacteremia , viremia , treat Febrile syndrome Tooth decay Once acute solve consider patient 's inclusion study Pregnant woman Pulmonary hypertension , increase 2 / 3 systemic pressure Eisenmenger syndrome Other associated heart disease , require surgical solution Immunocompromised patient Pathology oncology Hematologic coagulation disorder Allergy contrast medium Atypical calcify Ductus Parents legal guardian accept risk catheterization Parents legal guardian patient accept sign letter consent revoke consent . Patients participate another clinical investigation last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Ductus</keyword>
	<keyword>Patent ductus Arterious</keyword>
	<keyword>`` Nit-Occlud速 PDA-R ''</keyword>
	<keyword>Interventional closure PDA</keyword>
	<keyword>Percutaneous closure</keyword>
</DOC>